Vivex Biomedical Raises $7.4 Million
2013-09-18
细胞疗法
A biomedical startup that focuses on implant technology and stem cell therapies has raised $7.4 million, according to a Securities and Exchange Commission filing. Vivex Biomedical Inc. is developing implant technology to help stimulate bone regrowth. Vivex has also licensed a highly adaptive adult stem cell line, known as MIAMI (Marrow Isolated Adult Multi-lineage Inducible) cells. With its implant and stem cell technology, Vivex plans to target patients with spinal cord injuries, orthopedic injuries and traumatic wounds.
Help employers find you! Check out all the jobs and post your resume.
靶点
-药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。